Observational research presented in March 2026 at the American Academy of Orthopaedic Surgeons annual meeting found that GLP-1 drugs may slightly increase the risk of developing osteoporosis and gout, a kind of inflammatory arthritis caused by a buildup of uric acid
The starting dose of retatrutide, typically 1-2 mg, is deliberately conservative
As GLP-1 RAs are increasingly used in the treatment of T2DM, their potential carcinogenic and antineoplastic effects should be further investigated in future clinical studies
Efficacy and Safety Endpoints Researchers Track Retatrutide trials track endpoints such as percentage body-weight change, HbA1c, waist circumference, lipids, systolic blood pressure, liver fat, adverse events, serious adverse events, and treatment discontinuation [4], [5], [6], [7], [9]
Seek prompt medical attention if you experience pain in the upper right abdomen, pain radiating to the shoulder, yellowing of the skin or eyes (jaundice), or fever alongside abdominal pain